These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

702 related articles for article (PubMed ID: 9460772)

  • 1. The novel lipid delivery system of amphotericin B: drug profile and relevance to clinical practice.
    Rust DM; Jameson G
    Oncol Nurs Forum; 1998; 25(1):35-48. PubMed ID: 9460772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of liposomal amphotericin B formulation.
    Gulati M; Bajad S; Singh S; Ferdous AJ; Singh M
    J Microencapsul; 1998; 15(2):137-51. PubMed ID: 9532520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic and hemolytic evaluation of in-situ liposomal preparation containing amphotericin - beta complexed with different chemically modified beta - cyclodextrins.
    Chakraborty KK; Naik SR
    J Pharm Pharm Sci; 2003; 6(2):231-7. PubMed ID: 12935435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amphotericin B lipid complex versus liposomal amphotericin B monotherapy for invasive aspergillosis in patients with hematologic malignancy.
    Hachem RY; Boktour MR; Hanna HA; Husni RN; Torres HA; Afif C; Kontoyiannis DP; Raad II
    Cancer; 2008 Mar; 112(6):1282-7. PubMed ID: 18224662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety evaluation of ABELCET, an amphotericin B lipid complex (ABLC): toxicity studies in rats.
    Zhang Z; Diener RM; Lipman JM
    Int J Toxicol; 2006; 25(4):285-94. PubMed ID: 16815817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipid formulations of amphotericin B.
    Dix SP; Andriole VT
    Curr Clin Top Infect Dis; 2000; 20():1-23. PubMed ID: 10943516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What is the current and future status of conventional amphotericin B?
    Kleinberg M
    Int J Antimicrob Agents; 2006 Jun; 27 Suppl 1():12-6. PubMed ID: 16707251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients.
    Bowden R; Chandrasekar P; White MH; Li X; Pietrelli L; Gurwith M; van Burik JA; Laverdiere M; Safrin S; Wingard JR
    Clin Infect Dis; 2002 Aug; 35(4):359-66. PubMed ID: 12145716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liposomal and lipid-based formulations of amphotericin B.
    de Marie S
    Leukemia; 1996 Jun; 10 Suppl 2():s93-6. PubMed ID: 8649062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amphotericin B lipid complex (ABLC)-associated hypertension: case report and review.
    Rowles DM; Fraser SL
    Clin Infect Dis; 1999 Dec; 29(6):1564-5. PubMed ID: 10585814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Release of amphotericin B from delivery systems and its action against fungal and mammalian cells.
    Legrand P; Chéron M; Leroy L; Bolard J
    J Drug Target; 1997; 4(5):311-9. PubMed ID: 9169988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipid formulations of amphotericin B: recent progress and future directions.
    Hiemenz JW; Walsh TJ
    Clin Infect Dis; 1996 May; 22 Suppl 2():S133-44. PubMed ID: 8722841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liposomal drug delivery system from laboratory to clinic.
    Kshirsagar NA; Pandya SK; Kirodian GB; Sanath S
    J Postgrad Med; 2005; 51 Suppl 1():S5-15. PubMed ID: 16519249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipid formulations of amphotericin B as first-line treatment of zygomycosis.
    Petrikkos GL
    Clin Microbiol Infect; 2009 Oct; 15 Suppl 5():87-92. PubMed ID: 19754765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of liposomal amphotericin B versus an amphotericin B lipid complex on liver histopathology in patients with hematologic malignancies and invasive fungal infections: a retrospective, nonrandomized autopsy study.
    Chamilos G; Luna M; Lewis RE; Chemaly R; Raad II; Kontoyiannis DP
    Clin Ther; 2007 Sep; 29(9):1980-6. PubMed ID: 18035197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Study of the toxicity of a new lipid complex formulation of amphotericin B.
    Larabi M; Pages N; Pons F; Appel M; Gulik A; Schlatter J; Bouvet S; Barratt G
    J Antimicrob Chemother; 2004 Jan; 53(1):81-8. PubMed ID: 14657087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meta-analysis of nebulized amphotericin B to prevent or treat pulmonary aspergillosis in immunosuppressed animals.
    Ho KM; Duff O; Chambers D; Murray R
    Transpl Infect Dis; 2008 Jun; 10(3):168-76. PubMed ID: 18194368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liposomal amphotericin B (AmBisome) therapy in invasive fungal infections. Evaluation of United Kingdom compassionate use data.
    Ng TT; Denning DW
    Arch Intern Med; 1995 May; 155(10):1093-8. PubMed ID: 7748054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liposomal amphotericin B: clinical experience and perspectives.
    Gibbs WJ; Drew RH; Perfect JR
    Expert Rev Anti Infect Ther; 2005 Apr; 3(2):167-81. PubMed ID: 15918775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amphotericin B formulations: a comparative review of efficacy and toxicity.
    Hamill RJ
    Drugs; 2013 Jun; 73(9):919-34. PubMed ID: 23729001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.